ライフサイエンスコーパス: yellow fever vaccine

1 o adjuvanted vaccines or the live-attenuated yellow fever vaccine.

2 , robust response to MRKAd5/HIV with that to yellow fever vaccine.

3 nteers immunized with the highly efficacious yellow fever vaccine.

4 ation for at least 2 weeks after receiving a yellow fever vaccine.

5 s-mumps-rubella vaccine; 1 IPTT received the yellow fever vaccine.

6 epublic of Congo led to a global shortage of yellow fever vaccine.

7 ved with antibody responses to influenza and yellow fever vaccines.

8 The yellow fever vaccine 17D (17D) is safe, and after a sing

9 t transcriptomic gene expression profiles in Yellow Fever vaccine 17D (YF-17D) immunized human subjec

10 oenvironment to the response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort.

11 The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most eff

12 The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most eff

13 viral Ab responses, following infection with yellow fever vaccine 17D strain.

14 transfusion from a donor who had received a yellow fever vaccine 6 days before blood donation.

15 ology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope ge

16 Stocks of yellow fever vaccine are insufficient to cover exception

17 n with the Institut Pasteur de Dakar 17D-204 yellow fever vaccine at a standard dose (13,803 IU) or a

18 asles and rubella vaccine (first dose) and a yellow fever vaccine at age 9 months or with a measles a

19 IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when given as a fu

20 Vaccination with the yellow fever vaccine causes a systemic acute viral infec

21 As a result, a fractional dose of the 17DD yellow fever vaccine (containing one fifth [0.1 ml] of t

22 can underlie critical COVID-19 pneumonia and yellow fever vaccine disease.

23 on of the population who had ever received a yellow fever vaccine for each second level administrativ

24 Although a highly effective yellow fever vaccine has been available for more than se

25 Yellow fever vaccine has proven effective, but vaccinati

26 ly dynamic in humans after subcutaneous live yellow fever vaccine immunization.

27 serum in the 1918 flu epidemic, contaminated yellow fever vaccines in World War II, and unethical hum

28 acillus Calmette-Guerin (BCG), rotavirus and yellow fever vaccines, in terms of either immunogenicity

29 However, the yellow fever vaccine induced an early transient signatur

30 uration of protection after a single dose of yellow fever vaccine is a matter of debate.

31 Yellow fever vaccine is highly effective with a single d

32 whole-virus, beta-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and

33 with standard dose of four WHO-prequalified yellow fever vaccines produced from three substrains.

34 Yellow Fever vaccines should only be considered in egg-a

35 ned to receive the IPV, measles-rubella, and yellow fever vaccines, singularly or in combination.

36 2)-expressing plasmid (EP rDNA plus pIL-12), yellow fever vaccine virus 17D (rYF17D), and recombinant

37 The live-attenuated yellow fever vaccine virus 17D (YF17D) has many properti

38 We show that recombinant attenuated yellow fever vaccine virus 17D expressing simian immunod

39 eta production in response to CpG DNA or the yellow fever vaccine virus strain 17D.

40 A fractional dose of the 17DD yellow fever vaccine was effective at inducing seroconve

41 Symptoms associated with yellow fever vaccine were less frequent in the TY014 gro

42 Fractional doses of all WHO-prequalified yellow fever vaccines were non-inferior to the standard

43 and interferon gene program, similar to the yellow fever vaccine, which is known to confer long-last

44 -administration of IPV, measles-rubella, and yellow fever vaccines within the Expanded Programme on I

45 The yellow fever vaccine YF-17D is one of the most successfu

46 For example, the yellow fever vaccine YF-17D, one of the most successful

47 d immune responses in humans vaccinated with yellow fever vaccine YF-17D.

48 The live yellow fever vaccine (YF-17D) offers a unique opportunit

49 All participants received yellow fever vaccine (YF-17D; Sanofi Pasteur, Lyon, Fran

50 Institute of India, Pune, India) at week 0; yellow fever vaccine (YF-17D; Sanofi Pasteur, Lyon, Fran

51 iremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril).

52 Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal

53 The yellow fever vaccine (YFV) has been broadly used as a mo

54 dividuals immunized with the live attenuated yellow fever vaccine (YFV-17D) by sampling peripheral bl

55 dies that follow CD8 T cell responses to the yellow fever vaccine (YFV-17D).